we discussed a new hypothesis on the mechanism of action of atypical antipsychotics, namely the "hit-and-run" hypothesis. 2 Here we illustrate this concept. 
Conventional

Figure 2. Hypothetical Action of a Conventional Antipsychotic Over Time
Prior to dosing a schizophrenic patient with a conventional antipsychotic (A), there is no D 2 receptor blockade, and the schizophrenic patient has positive symptoms of psychosis such as delusions and auditory and visual hallucinations. Also, in the absence of drug, there will be no extrapyramidal motor side effects (EPS) (shown by a slash through the patient with parkinsonism). After a dose of a conventional antipsychotic (B), D 2 receptors are blocked so tightly that they both cause antipsychotic actions and induce EPS. After another dose of a conventional antipsychotic (C), the D 2 receptors stay persistently blocked, so that antipsychotic actions are always associated with EPS.
Prior to dosing a schizophrenic patient with an atypical antipsychotic (A), there is no D 2 receptor blockade, and the schizophrenic patient has positive symptoms of psychosis, just as with a conventional agent as shown above. Also, in the absence of drug, there will be no extrapyramidal motor side effects (EPS). After a dose of an atypical antipsychotic (B), D 2 receptors are blocked initially, but become unblocked when the drug slides off the receptor. Theoretically, antipsychotic actions require only initial blockade of D 2 receptors, whereas EPS require persistent blockade of D 2 receptors. Since the nature of atypical antipsychotic binding is to rapidly dissociate from D 2 receptors after binding to them, these drugs can have antipsychotic actions without inducing EPS by hitting the D 2 receptor hard enough to cause antipsychotic effects and then running before they cause EPS. Since this happens dose after dose (C), antipsychotic actions are persistent and long lasting, but EPS do not develop over time. 
